Wen-miao Wang

Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer

F. Du, Bing-he Xu, P. Yuan, 2020, Breast Cancer Research and Treatment.

Management of Contralateral Axillary Lymph Node Metastasis from Breast Cancer: A Clinical Dilemma

Bing-he Xu, P. Yuan, F. Ma, 2014, Tumori.

Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up

F. Du, Bing-he Xu, P. Yuan, 2021, Breast Cancer Research and Treatment.

A single-nucleotide polymorphism in the 3′-UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer

D. Lin, Dianke Yu, F. Du, 2016, Oncotarget.

Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA

G. Lippi, Yang Luo, Bing-he Xu, 2021, Cancer biology & medicine.

A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients

Jun Ren, L. Di, Jing Yu, 2015, SpringerPlus.